Biotechnology and Pharmaceuticals
in the Capital Region Berlin-Brandenburg
Leading European location for biotechnology

Biotechnology is an engine of innovation in the Berlin-Brandenburg region. The sector is recording steady growth and a high rate of company start-ups. This positive trend is based on the region’s excellent research landscape and technology parks specialized in biotechnology. They provide optimal conditions for start-ups and large, research-intensive companies alike. Of the more than 230 biotechnology companies with approx. 4,600 employees here, 80% focus on biomedicine. They develop innovative therapeutic and diagnostic procedures for the treatment of cancer, cardiovascular diseases and diabetes, and benefit from the region’s excellent science and top infrastructure for clinical studies. Berlin-Brandenburg possesses expertise in genome and proteome research, diagnostics, regenerative medicine, RNA technologies and glyco-engineering technology.

Pharmaceuticals location with a rich history and modern dynamics

The sustained success of pharmaceuticals companies in Berlin and Brandenburg is based on innovative products and a venerable tradition reaching back to the 19th century. The sector benefits from an excellent scientific environment and clinical research landscape, and its proximity to the health care system decision makers. This applies to global players such as Bayer, Pfizer, Sanofi, Takeda and Berlin-Chemie (Menarini) and to more than 20 additional medium-sized pharmaceutical companies with a total of 10,000 employees. Many international corporations such as Daiichi Sankyo and Astra Zeneca also have representative offices in Berlin.

Bayer HealthCare Pharmaceuticals can look back at a long history in Berlin. Today, the company is one of the world’s 10 largest specialty pharmaceuticals companies. More than 1,000 Sanofi employees manage the company’s marketing and sales activities in Berlin. In 2011, Takeda Pharma took over the Nycomed Group and only one year later, moved its sales headquarters to Berlin. Takeda is currently investing €100 million to expand its production facilities in Oranienburg. Pharmaceuticals giant Pfizer is also expanding its activities in the
capital region, establishing other business units to supplement its German headquarters here. For example, the company manages its oncology business unit for Europe from Berlin. In 2014, the French-American joint venture Sanofi Pasteur MSD decided to move its German headquarters to Berlin – as did Riemser Pharma, which is reinforcing its sales activities with an operations-related unit in Berlin. Berlin-Chemie is investing €80 million to expand its production facilities in the south of Berlin. Dr. Kade, which has been growing in the capital region for over 25 years, has taken over Takeda’s OTC business. And the fact that Klosterfrau Berlin invested in a new production hall in 2013 also shows that Berlin has developed into an important production location in recent years.

**Clinical research**
The close connection between research, development and the clinics here is most obviously demonstrated by the region’s successful, well-established translational research and the wide range of opportunities available for implementing clinical studies. With its large, extremely diverse patient collective, Berlin-

### Optimal conditions for start-ups
The seven biotechnology parks in the region provide optimal conditions for young, growing companies. Over 50% of the biotechnology companies use the programs of the state-owned or privately operated parks, which offer a variety of contextual focal areas. In addition to the availability of laboratory space and an extensive technical infrastructure, they benefit from the close contact and intense exchange with the research institutions and multi-faceted service providers that are also located in the parks.

When it comes to early stage financing, the states’ own business development banks have investment companies whose technology funds play an important role. Projects such as Bayer’s CoLaborator are evidence of the major pharmaceuticals corporations’ involvement.
Our aim: your success!

Berlin and Brandenburg support the biotechnology and pharma focal area with an economic policy developed across state borders in the Healthcare industries cluster. The cluster is managed under the aegis of Berlin Partner for Business and Technology and ZAB ZukunftsAgentur Brandenburg.

Our aim is to provide comprehensive support to companies and scientific institutions interested in inward investment or further development in the capital region.

We are ready to assist you with:

- Company start-up
- Location search
- Funding and financing
- Technology transfer and R&D partnerships
- Cooperating in networks
- Employee recruiting, programs designed to retain skilled specialists and qualification
- International market development

Reach out and contact us!
www.healthcapital.de